Bingying Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bingying Zhou has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Rongjia Rao
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College 167 North Lishi Road, Xicheng District
9 shared publicationsChao Tong
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China
6 shared publicationsWei Feng
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
6 shared publicationsXianqiang Wang
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
6 shared publicationsZhan Hu
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
6 shared publicationsDandan Li
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 shared publications
Latest Publications
- 23 October 2026
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 201, 107055
MAF transcription factors: Emerging key players in cardiovascular health and disease
- 23 October 2026
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 201, 107055
MAF transcription factors: Emerging key players in cardiovascular health and disease
- 9 July 2026
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 9 (15) , 6901-6917
Enhanced Tear Resistance and Biocompatibility of Polyurethane-Urea Elastomers for Artificial Heart Valves via Hydrogen Bonding Design
Valvular heart disease imposes a heavy global clinical burden, and conventional mechanical and bioprosthetic valves struggle to achieve an optimal balance between long-term durability and in vivo biocompatibility. Siloxane polyurethane urea (SiPUU) serves as a commonly used polymer matrix for heart valve research owing to its intrinsic favorable cytocompatibility. Nevertheless, its insufficient tear resistance and inferior cyclic fatigue properties render it incompatible with the surgical suturing and forming procedures of prosthetic heart valves. To overcome the mechanical bottlenecks of existing polyurethane valve materials, we engineered a library of polyurethane-urea thermoplastic elastomers (Fuwai Material (J), FWJ series) by embedding abundant N–H moieties along the polymer backbone to amplify intermolecular hydrogen-bonding interactions. The top-performing variant 2NO-FWJ delivers a suite of valve-matching superior mechanical properties: a tear strength of 158.64 N/mm (55.07% higher than conventional polyurethane matrices), an elongation at break of 1686.80%, and a Young′s modulus of 15.74 MPa. Under simulated physiological circulation, the material maintains robust structural integrity beyond 200 million fatigue cycles while presenting ideal hemodynamic metrics (effective orifice area ≥1.99 cm2 and transvalve pressure differential ≤11.6 mmHg). Distinct from prior polymer biocompatibility assessments relying on immortalized cell lines, this work pioneers biocompatibility characterization utilizing multiple types of primary human cardiac cells. In vitro biological characterizations suggest that 2NO-FWJ displays mild cellular toxicity, limited protein adhesion, moderate antidegradation ability against enzymes, and favorable hemocompatibility. Benefiting from hydrogen-bond-reinforced intermolecular networks, the developed FWJ elastomers simultaneously resolve the insufficient tear resistance and poor long-term fatigue durability of prevailing polymeric valve substrates and display immense translational potential for surgical suturable artificial heart valve fabrication.
- 9 July 2026
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 9 (15) , 6901-6917
Enhanced Tear Resistance and Biocompatibility of Polyurethane-Urea Elastomers for Artificial Heart Valves via Hydrogen Bonding Design
Valvular heart disease imposes a heavy global clinical burden, and conventional mechanical and bioprosthetic valves struggle to achieve an optimal balance between long-term durability and in vivo biocompatibility. Siloxane polyurethane urea (SiPUU) serves as a commonly used polymer matrix for heart valve research owing to its intrinsic favorable cytocompatibility. Nevertheless, its insufficient tear resistance and inferior cyclic fatigue properties render it incompatible with the surgical suturing and forming procedures of prosthetic heart valves. To overcome the mechanical bottlenecks of existing polyurethane valve materials, we engineered a library of polyurethane-urea thermoplastic elastomers (Fuwai Material (J), FWJ series) by embedding abundant N–H moieties along the polymer backbone to amplify intermolecular hydrogen-bonding interactions. The top-performing variant 2NO-FWJ delivers a suite of valve-matching superior mechanical properties: a tear strength of 158.64 N/mm (55.07% higher than conventional polyurethane matrices), an elongation at break of 1686.80%, and a Young′s modulus of 15.74 MPa. Under simulated physiological circulation, the material maintains robust structural integrity beyond 200 million fatigue cycles while presenting ideal hemodynamic metrics (effective orifice area ≥1.99 cm2 and transvalve pressure differential ≤11.6 mmHg). Distinct from prior polymer biocompatibility assessments relying on immortalized cell lines, this work pioneers biocompatibility characterization utilizing multiple types of primary human cardiac cells. In vitro biological characterizations suggest that 2NO-FWJ displays mild cellular toxicity, limited protein adhesion, moderate antidegradation ability against enzymes, and favorable hemocompatibility. Benefiting from hydrogen-bond-reinforced intermolecular networks, the developed FWJ elastomers simultaneously resolve the insufficient tear resistance and poor long-term fatigue durability of prevailing polymeric valve substrates and display immense translational potential for surgical suturable artificial heart valve fabrication.
- Open Access
- 26 June 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Correction to: SIRT3 activation protects from nabumetone-induced mitochondrial toxicity in adult human cardiomyocytes
- 26 June 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Open AccessCorrection to: SIRT3 activation protects from nabumetone-induced mitochondrial toxicity in adult human cardiomyocytes
- Open Access
- 17 April 2026
- Published by Wiley in Physiological Reports
- Vol. 14 (8) , e70877
Ponatinib confers adult human cardiomyocyte toxicity via inhibition of AKT signaling
As a widely used anticancer drug for the treatment of chronic myeloid leukemia, ponatinib is known to cause severe cardiovascular toxicities. Cardiomyocytes are the major functional units in the myocardium, and impairment of their viability and function plays a crucial role in cardiotoxic responses. Previous studies have indicated direct toxicity of ponatinib on cardiomyocytes, but the effect of ponatinib on adult human primary cardiomyocytes (hPCMs) remains unknown, largely due to sample scarcity and the technical challenges associated with the adult human cardiomyocyte model. Based upon our previous work establishing hPCMs as a pharmacologically competent model, we tested the direct toxicity of ponatinib on these cells. We reveal suppression of AKT, but not ERK, phosphorylation upon ponatinib treatment. Treatment of hPCMs with AKT inhibitor MK‐2206 phenocopied ponatinib, while restoration of AKT signaling with UCL‐TRO‐1938 or insulin partially rescued hPCMs from cell death, suggesting a potential protective effect.
- 17 April 2026
- Published by Wiley in Physiological Reports
- Vol. 14 (8) , e70877
Open AccessPonatinib confers adult human cardiomyocyte toxicity via inhibition of AKT signaling
As a widely used anticancer drug for the treatment of chronic myeloid leukemia, ponatinib is known to cause severe cardiovascular toxicities. Cardiomyocytes are the major functional units in the myocardium, and impairment of their viability and function plays a crucial role in cardiotoxic responses. Previous studies have indicated direct toxicity of ponatinib on cardiomyocytes, but the effect of ponatinib on adult human primary cardiomyocytes (hPCMs) remains unknown, largely due to sample scarcity and the technical challenges associated with the adult human cardiomyocyte model. Based upon our previous work establishing hPCMs as a pharmacologically competent model, we tested the direct toxicity of ponatinib on these cells. We reveal suppression of AKT, but not ERK, phosphorylation upon ponatinib treatment. Treatment of hPCMs with AKT inhibitor MK‐2206 phenocopied ponatinib, while restoration of AKT signaling with UCL‐TRO‐1938 or insulin partially rescued hPCMs from cell death, suggesting a potential protective effect.
- Open Access
- 10 March 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
SIRT3 activation protects from nabumetone-induced mitochondrial toxicity in adult human cardiomyocytes
Drug-induced mitochondrial toxicity is a major contributing factor to cardiotoxicity, which can cause drug attrition and adverse cardiac events. To assess the toxicity of anti-inflammatory agents, we used adult human primary cardiomyocytes (hPCMs) to screen 18 clinically available anti-inflammatory drugs in a high-content manner, and revealed widespread mitochondrial dysfunction without affecting cell viability. Nabumetone, a representative nonsteroidal anti-inflammatory drug with profound mitochondrial toxicity, induced mitochondrial fission, inhibited mitophagy, and impaired both electrophysiological and metabolic functions in adult hPCMs. Mechanistically, we uncovered that nabumetone (Nab) exerted its toxic effects through the prostaglandin E2- E-type prostanoid receptor 4 (PGE2-EP4) pathway, which was essential for its anti-inflammatory functions. To find an alternative route to ameliorate mitochondrial damage, we identified SIRT3 as a downstream target of nabumetone. Its mRNA, protein, and activity levels were significantly reduced upon nabumetone treatment. SIRT3 activator honokiol exhibited protective potential against NSAID-induced mitochondrial toxicity both in hPCMs and in nabumetone-treated mice. Finally, through screening mitochondrial liability in various common cardiomyocyte models, we identified mitochondrial abundance as an important determinant of the sensitivity of cells towards mitochondrial toxicants. Our study demonstrates the vast presence of mitochondrial dysfunction in human adult cardiomyocytes imposed by clinically used anti-inflammatory drugs, and identified both toxicity and protective pathways that may serve future therapeutic purposes.
- 10 March 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Open AccessSIRT3 activation protects from nabumetone-induced mitochondrial toxicity in adult human cardiomyocytes
Drug-induced mitochondrial toxicity is a major contributing factor to cardiotoxicity, which can cause drug attrition and adverse cardiac events. To assess the toxicity of anti-inflammatory agents, we used adult human primary cardiomyocytes (hPCMs) to screen 18 clinically available anti-inflammatory drugs in a high-content manner, and revealed widespread mitochondrial dysfunction without affecting cell viability. Nabumetone, a representative nonsteroidal anti-inflammatory drug with profound mitochondrial toxicity, induced mitochondrial fission, inhibited mitophagy, and impaired both electrophysiological and metabolic functions in adult hPCMs. Mechanistically, we uncovered that nabumetone (Nab) exerted its toxic effects through the prostaglandin E2- E-type prostanoid receptor 4 (PGE2-EP4) pathway, which was essential for its anti-inflammatory functions. To find an alternative route to ameliorate mitochondrial damage, we identified SIRT3 as a downstream target of nabumetone. Its mRNA, protein, and activity levels were significantly reduced upon nabumetone treatment. SIRT3 activator honokiol exhibited protective potential against NSAID-induced mitochondrial toxicity both in hPCMs and in nabumetone-treated mice. Finally, through screening mitochondrial liability in various common cardiomyocyte models, we identified mitochondrial abundance as an important determinant of the sensitivity of cells towards mitochondrial toxicants. Our study demonstrates the vast presence of mitochondrial dysfunction in human adult cardiomyocytes imposed by clinically used anti-inflammatory drugs, and identified both toxicity and protective pathways that may serve future therapeutic purposes.
- 19 January 2026
- Published by Elsevier in Cryobiology
- Vol. 122, 105583
Optimized methods for the functional cryopreservation of adult human primary cardiomyocytes
- 19 January 2026
- Published by Elsevier in Cryobiology
- Vol. 122, 105583
Optimized methods for the functional cryopreservation of adult human primary cardiomyocytes
- Open Access
- 27 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1
Author Correction: Serpina3k lactylation protects from cardiac ischemia reperfusion injury
- 27 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1
Open AccessAuthor Correction: Serpina3k lactylation protects from cardiac ischemia reperfusion injury
- Top Cited PapersOpen Access
- 25 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-21
Serpina3k lactylation protects from cardiac ischemia reperfusion injury
Lactate produced during ischemia-reperfusion injury is known to promote lactylation of proteins, which play controversial roles. By analyzing the lactylomes and proteomes of mouse myocardium during ischemia-reperfusion injury using mass spectrometry, we show that both Serpina3k protein expression and its lactylation at lysine 351 are increased upon reperfusion. Both Serpina3k and its human homolog, SERPINA3, are abundantly expressed in cardiac fibroblasts, but not in cardiomyocytes. Biochemically, lactylation of Serpina3k enhances protein stability. Using Serpina3k knockout mice and mice overexpressing its lactylation-deficient mutant, we find that Serpina3k protects from cardiac injury in a lysine 351 lactylation-dependent manner. Mechanistically, ischemia-reperfusion-stimulated fibroblasts secrete Serpina3k/SERPINA3, and protect cardiomyocytes from reperfusion-induced apoptosis in a paracrine fashion, partially through the activation of cardioprotective reperfusion injury salvage kinase and survivor activating factor enhancement pathways. Our results demonstrate the pivotal role of protein lactylation in cardiac ischemia-reperfusion injury, which may hold therapeutic value.
- 25 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-21
Top Cited PapersOpen AccessSerpina3k lactylation protects from cardiac ischemia reperfusion injury
Lactate produced during ischemia-reperfusion injury is known to promote lactylation of proteins, which play controversial roles. By analyzing the lactylomes and proteomes of mouse myocardium during ischemia-reperfusion injury using mass spectrometry, we show that both Serpina3k protein expression and its lactylation at lysine 351 are increased upon reperfusion. Both Serpina3k and its human homolog, SERPINA3, are abundantly expressed in cardiac fibroblasts, but not in cardiomyocytes. Biochemically, lactylation of Serpina3k enhances protein stability. Using Serpina3k knockout mice and mice overexpressing its lactylation-deficient mutant, we find that Serpina3k protects from cardiac injury in a lysine 351 lactylation-dependent manner. Mechanistically, ischemia-reperfusion-stimulated fibroblasts secrete Serpina3k/SERPINA3, and protect cardiomyocytes from reperfusion-induced apoptosis in a paracrine fashion, partially through the activation of cardioprotective reperfusion injury salvage kinase and survivor activating factor enhancement pathways. Our results demonstrate the pivotal role of protein lactylation in cardiac ischemia-reperfusion injury, which may hold therapeutic value.
- Open Access
- 17 December 2024
- Published by Elsevier in Journal of Molecular and Cellular Cardiology Plus
- Vol. 11, 100278
Cardioprotective strategies in myocardial ischemia-reperfusion injury: Implications for improving clinical translation
- 17 December 2024
- Published by Elsevier in Journal of Molecular and Cellular Cardiology Plus
- Vol. 11, 100278
Open AccessCardioprotective strategies in myocardial ischemia-reperfusion injury: Implications for improving clinical translation
- Open Access
- 16 October 2024
- Published by Elsevier in STAR Protocols
- Vol. 5 (4) , 103379
Protocol for the dissociation of adult human primary cardiomyocytes using a methylcellulose-supplemented digestion solution
- 16 October 2024
- Published by Elsevier in STAR Protocols
- Vol. 5 (4) , 103379
Open AccessProtocol for the dissociation of adult human primary cardiomyocytes using a methylcellulose-supplemented digestion solution